
Shortage of verteporfin limits treatment options for central serous chorioretinopathy (CSC), a common eye condition. Researchers assessed topical non-steroidal anti-inflammatory drugs (NSAIDs) as an alternative. Thirteen studies, involving 1001 eyes of 994 CSC patients, were analyzed. While some improvement in visual acuity was noted at 1-month follow-up, it became insignificant at 3 months. The subretinal fluid resolution also showed no significant benefit. This systematic review and meta-analysis concluded that existing evidence does not back the use of topical NSAIDs for CSC treatment. The study highlights ongoing challenges in managing this condition.
Like
Save
Share